Myeloablative conditioning regimen    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
164Oculocutaneous albinism1

164. Oculocutaneous albinism    [ 15 clinical trials,   57 drugs,   (DrugBank: 34 drugs),   34 drug target genes,   136 drug target pathways]
Searched query = "Oculocutaneous albinism", "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Griscelli syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 15 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00176826
(ClinicalTrials.gov)
September 200012/9/2005T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic DisordersIn-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic DisordersHemophagocytic Lymphohistiocytosis;X-Linked Lymphoproliferative Disorders;Chediak-Higashi Syndrome;Griscelli Syndrome;Immunologic Diseases;Langerhans-Cell Histiocytosis;Hematologic DiseasesProcedure: Stem Cell Transplant;Drug: Myeloablative conditioning regimenMasonic Cancer Center, University of MinnesotaNULLUnknown statusN/A55 YearsAll22Phase 2;Phase 3United States